Company profile
Embecta Corp.
NASDAQ: EMBC · Healthcare · Drug Manufacturers - Specialty & Generic
#151 of 1,418 Healthcare companies by revenue36th-percentile growth
EA Score
67BFH 87DQ 46GM 57SS 57
v0.1 · 65/100 weight · provisional
↑ growth stability, operating margin · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$1.0B
Rev growth YoY (TTM)
-3.4%
Net income (FY)
$95.4M
Employees
1,850
as of 2026-08-13
Market cap
$281.8M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.1B$1.1B2025
Net income$95.4M$95.4M2025
Operating income$242.1M$242.1M2025
Total assets$1.1B$1.1B2025
Equity-$650.6M-$650.6M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Safety80%
Manufacturing Facility12%
Product and Service, Other8%
By geography
UNITED STATES54%
Non-US46%
The read
What is Embecta Corp.’s revenue?
Embecta Corp. booked $1.1B in FY2025 revenue, contracting 3.8% year over year — slower than 64% of Healthcare companies we track, at a 8.8% net margin.
Peers · Healthcare
Babylon Holdings Limited——Waystar Holding Corp.70BPrestige Consumer Healthcare Inc.79B+ACADIA Pharmaceuticals Inc.82B+Bone Biologics Corporation45DTandem Diabetes Care, Inc.67BNeighbors
Morris →Key facts
CEODevdatt Kurdikar
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersParsippany, NJ
ExchangeNASDAQ: EMBC
Employees1,850
IPO date2022-03-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.